Former FDA Commissioner Dr. David Kessler has just released an important new book on diet and wieght loss. He spoke to Forbes ...

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Embecta stock may seem undervalued at first glance, but heavy debt, declining pen needle revenues, and competition signal ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1 study in obese or overweight individuals; top-line ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Cencora, Inc. COR reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $4.42, which beat the Zacks ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

which will dispense GLP-1s and be operated by clinicians who can support patients with GLP-1 education and support. “We developed these programs really in response to some of the clear needs ...

Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists. (HealthDay News) — Many Medicaid ...